Oral News and Research

RSS

Breast tenderness indicates increased cancer risk among women on combination therapy

Women who developed new-onset breast tenderness after starting estrogen plus progestin hormone replacement therapy were at significantly higher risk for developing breast cancer than women on the combination therapy who didn't experience such tenderness, according to a new UCLA study.

13 Oct 2009

Positive results from Alkermes' ALKS 33 clinical trials announced

Alkermes, Inc. today announced positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorders. Data from the studies, ALK33-003 and ALK33-004, showed that ALKS 33 was generally well tolerated and successfully blocked the effects of an opioid, with a duration of action that supports once daily dosing.

13 Oct 2009

Vioguard launches the first self-sanitizing computer keyboard

Vioguard LLC, www.vioguard.com, is introducing the world’s first self-sanitizing computer keyboard to kill MRSA and other healthcare-associated infections (HAIs) at the American Association of Oral and Maxillofacial Surgeons (AAOMS) 91st annual meeting, October 12-17 in Toronto. The event marks the first availability of the innovative keyboard for medical market uses and consumers in Canada.

13 Oct 2009

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc.

13 Oct 2009

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

Merck Frosst Canada Ltd. announced today that its new diabetes treatment, JANUMET(TM) (sitagliptin/metformin HCI, MSD), has received Notice of Compliance (NoC) in Canada.

13 Oct 2009

Guidelines for treating amyotrophic lateral sclerosis identified

New guidelines from the American Academy of Neurology identify the most effective treatments for amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease. The guidelines are published in the October 13, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology.

13 Oct 2009

New guidelines for treating amyotropic lateral sclerosis

Dr. John England, Professor and Chairman of Neurology at LSU Health Sciences Center New Orleans, analyzed research findings and was responsible for the quality and accuracy of evidence analysis and the conclusions of the studies resulting in new guidelines for treating Lou Gehrig's disease, or amyotropic lateral sclerosis (ALS).

13 Oct 2009

Study demonstrates coexistence of visuospatial and phonological disorders in dyslexics

Chinese-speaking children with dyslexia have a disorder that is distinctly different, and perhaps more complicated and severe, than that of English speakers. Those differences can be seen in the brain and in the performance of Chinese children on visual and oral language tasks, reveals a report published online on October 12th in Current Biology, a Cell Press publication.

13 Oct 2009

Majority of Americans agree that children should get good dental care and medical care

Nearly nine in 10 Americans agree that it's equally important for their children to get good dental care and medical care.

12 Oct 2009

Arena Pharmaceuticals to present Phase 3 BLOSSOM trial results at Obesity 2009

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that lorcaserin will be featured in multiple presentations at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society in Washington, DC.

12 Oct 2009

Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical

Raptor Pharmaceutical Corp., announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate ("DR Cysteamine") in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 2% to 5% of the U.S. population.

12 Oct 2009

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Nektar Therapeutics presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona.

12 Oct 2009

Public forum and scientific workshop on women's health issues

The Northwestern University Feinberg School of Medicine and Northwestern Memorial Hospital will host a public forum and scientific workshop Oct. 14 to 16 to discuss emerging issues of importance for the National Institutes of Health (NIH) for women's health research in the coming decade.

12 Oct 2009

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Crescendo Biologics today announces it has raised GBP4.5 million in a seed-funding round to advance the development of its fragment antibody technology platforms. The funding round was led by Sofinnova Partners, a Paris-based venture capital firm, with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating.

12 Oct 2009

Bad breath can be treated

All of us have experienced bad breath at some point. However, suffering from chronic bad breath, or halitosis, can be embarrassing and affect your self-esteem and relationships with family, friends and coworkers. The good news -- bad breath is often preventable and easily treated.

12 Oct 2009

Phase I clinical trial results for Fentanyl Lauriad announced by BioAlliance Pharma

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency (AFSSaPS) to enter first Phase I clinical trial for Fentanyl Lauriad®.

12 Oct 2009

Presentations on efficacy of interferon to combat influenza

Amarillo Biosciences, Inc. (ABI) today announced that Professor Dr. Otto Haller from the Department of Virology, Freiburg University, Germany and Professor Dr. Oliver Planz from the Friedrich Loeffler Institute, Tubingen, Germany gave two separate presentations on the efficacy of interferon to combat influenza.

12 Oct 2009

Wal-Mart Stores to offer Tamiflu oral suspension in liquid form for children and elderly

Wal-Mart Stores, Inc. announced today that more than 4,000 Walmart and Sam's Club pharmacies nationwide will address the national shortage of Tamiflu® oral suspension by converting the capsule to liquid form.

12 Oct 2009

NIH launches trial for the determination of 2009 H1N1 influenza vaccine for asthma patients

The National Institutes of Health is preparing to launch the first government-sponsored clinical trial to determine what dose of the 2009 H1N1 influenza vaccine is needed to induce a protective immune response in people with asthma, especially those with severe disease.

12 Oct 2009

Clinical trial reveals cholera vaccine is safe, offers protection for up to 2 years

A clinical trial of an Indian-made "modified killed-whole-cell" oral cholera vaccine "that meets WHO standards" has found that the vaccine is safe and effective in children living in parts of India where the disease is endemic, Reuters reports. The researchers, who reported their findings in the journal Lancet, hope to soon introduce the vaccine into other cholera endemic settings.

9 Oct 2009

Oral News and Research

Breast tenderness indicates increased cancer risk among women on combination therapy

Positive results from Alkermes' ALKS 33 clinical trials announced

Vioguard launches the first self-sanitizing computer keyboard

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

Guidelines for treating amyotrophic lateral sclerosis identified

New guidelines for treating amyotropic lateral sclerosis

Study demonstrates coexistence of visuospatial and phonological disorders in dyslexics

Majority of Americans agree that children should get good dental care and medical care

Arena Pharmaceuticals to present Phase 3 BLOSSOM trial results at Obesity 2009

Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Public forum and scientific workshop on women's health issues

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Bad breath can be treated

Phase I clinical trial results for Fentanyl Lauriad announced by BioAlliance Pharma

Presentations on efficacy of interferon to combat influenza

Wal-Mart Stores to offer Tamiflu oral suspension in liquid form for children and elderly

NIH launches trial for the determination of 2009 H1N1 influenza vaccine for asthma patients

Clinical trial reveals cholera vaccine is safe, offers protection for up to 2 years

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News